✦ LIBER ✦

A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

✍ Scribed by Kim, Dong-Wan; Lee, Se-Hoon; Lee, Jong Seok; Lee, Myung Ah; Kang, Jin Hyoung; Kim, Si Young; Shin, Sang Won; Kim, Hoon-Kyo; Heo, Dae Seog

Book ID: 117989874
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 433 KB
Volume: 71
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2010.04.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

LUX-lung 3: A randomized, open-label, ph

LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations

✍ Schuler, Martin; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O’Byrne, Ken; Hirsh, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 53 KB

9123 POSTER Final Results of a Phase II

9123 POSTER Final Results of a Phase II Study of Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Non-small Cell Lung Cancer – Gefitinib for Elderly Patients With Lung Adenocarcinoma

✍ Asami, K.; Koizumi, T.; Hirai, K.; Ameshima, S.; Tsukadaira, A.; Morozumi, N.; M 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

A phase II, open-label, multicenter stud

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression

✍ Li, D.; Pant, S.; Ryan, D.P.; Laheru, D.; Bahary, N.; Dragovich, T.; Hosein, P.J 📂 Article 📅 2014 🏛 S. Karger AG 🌐 English ⚖ 222 KB